<DOC>
	<DOCNO>NCT00151697</DOCNO>
	<brief_summary>Many diabetic gain weight insulin therapy . In study , evaluate efficacy combination glimepiride short-acting insulin weight control glucose control . In study , 150 diabetic whose diabetic control inadequate maximal oral treatment randomize either new combination treatment twice daily injection mixture short- longacting insulin once-daily injection basal insulin analog . The study compare glucose control weight gain year randomisation three treatment .</brief_summary>
	<brief_title>LANN-study : Lantus , Amaryl , Novorapid , Novomix Study</brief_title>
	<detailed_description>Diabetic patient fail maximal oral treatment usually switch twice daily administration mixture short- longacting insulin . Although improves glycemic control , generally accompany substantial gain body weight . This may lead increase body fat result worsen insulin resistance , lead increase insulin dose need maintain glycemic control . The combination glimepiride ( amaryl ) short-acting insulin ( novorapid ) think attain glycemic control small increase body weight . In randomized controlled trial , 150 diabetic fail maximal oral treatment randomize preprandial use Novorapid combine Amaryl 20.00 hour , twice daily Novomix 30 , daily Lantus . Metformin continue . In year randomisation , patient follow glycemic control , body weight , body composition , record number hypoglycemic event , plasma lipid level , basal stimulate C-peptide level adverse effect .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>fail maximal oral treatment , define mean fasting blood glucose 8 mmol/l HbA1C 7.5 % three month BMI 25 35 kg/m2 fast plasma Cpeptide level 0.3 nmol/l stable metformin sulfonylurea dose least three month stable weight least three month ( change maximal 2 kg ) fast glucose 25 mmol/l use alphaglucosidase inhibitor thiazolidinediones two month precede study renal liver failure define serum creatinine 150 micromol/l , liver enzymes 1.5 upper normal limit heart failure pregnancy alcohol two unit per day inflammatory infectious disease unstable chronic disease discontinuation smoking within three month randomisation date allergy intolerance glimepiride novorapid .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>diabetes</keyword>
	<keyword>fail oral treatment</keyword>
	<keyword>weight gain</keyword>
</DOC>